Chainlink brings U.S. stocks and ETF pricing onchain with 24/5 data streams
Chainlink has announced new onchain data streams for U.S. stocks and ETFs aimed at helping crypto products track traditional-market prices more accurately. The company says the offering covers major U.S. names and runs 24 hours a day, five days a week, including extended trading sessions outside regular market hours.
The product, called 24/5 U.S. Equities Streams, expands Chainlink’s market data lineup for crypto platforms. Company says these feeds can be used to build trading, lending, and derivatives products where the underlying is a tokenized stock or ETF.
The company points to a structural mismatch: blockchains run nonstop, while U.S. equities trade on a set schedule. That gap has forced many onchain products into downtime windows, when pricing updates become sparse or stale.
Chainlink argues that this has been one of the reasons U.S. equities haven’t moved onchain faster. With crypto markets operating around the clock, the company says demand is rising for steady, high-frequency equity data especially as platforms experiment with “always-on” markets and instruments like perpetual-style products that reference stocks.
Company also listed early integrations, including Lighter, BitMEX, ApeX, HelloTrade, Decibel, Monaco, Opinion Labs, and Orderly Network. These teams plan to use the new streams to power products tied to U.S.-listed assets.
Chainlink added that 24/5 coverage is a starting point. Next, it plans to broaden the offering to more asset classes and regions and move toward 24/7 onchain coverage over time.
The material on GNcrypto is intended solely for informational use and must not be regarded as financial advice. We make every effort to keep the content accurate and current, but we cannot warrant its precision, completeness, or reliability. GNcrypto does not take responsibility for any mistakes, omissions, or financial losses resulting from reliance on this information. Any actions you take based on this content are done at your own risk. Always conduct independent research and seek guidance from a qualified specialist. For further details, please review our Terms, Privacy Policy and Disclaimers.
Articles by this author
